Dr. Kim's goal is to develop chimeric antigen receptor T cells as a safe and effective therapy for AML. To this end, I am exploring different target antigens for CAR T cell therapy, investigating mechanisms to enhance the anti-tumor effect of CAR T cells, and finding methods to circumvent the toxicity associated with T cell immunotherapy in the setting of myeloid malignancies.

Get the latest thought leadership on AML delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.

Thanks to our HealthTree Community for AML Sponsors:

Bristol Myers Squibb
Jazz Pharmaceuticals

Follow Us

facebook instagram twitter youtube


Terms of Use and Privacy Policy     Newsroom     About    Donations    Find an AML Specialist     Newsletter     Learn     Connect


Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811